Join to View Full Profile
450 Brookline AveDa930Boston, MA 02215
Phone+1 617-632-6328
Fax+1 617-632-2165
Dr. Choudhury is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
Columbia University Vagelos College of Physicians and SurgeonsClass of 2006
Certifications & Licensure
MA State Medical License 2009 - 2027
NH State Medical License 2024 - 2026
RI State Medical License 2022 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2015, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2015, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015, 2017
Clinical Trials
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 May 29
- Abemaciclib With or Without Atezolizumab for mCRPC Start of enrollment: 2021 Aug 20
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Start of enrollment: 2021 Jun 28
Publications & Presentations
PubMed
- Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate...Autumn Gagnon, Caiwei Zhong, Wanling Xie, Lynne Morlock, Dory Freeman
Prostate Cancer and Prostatic Diseases. 2026-06-01 - Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.Autumn Gagnon, Caiwei Zhong, Wanling Xie, Lynne Morlock, Dory Freeman
Prostate Cancer and Prostatic Diseases. 2026-06-01 - Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer.David D Chen, Anat Zimmer, David D Yang, Edoardo Francini, Robert Patton
NPJ Precision Oncology. 2026-04-28
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Press Mentions
Here Are Warning Signs That Men Age 15-35 Need to Know About Testicular CancerApril 7th, 2023- The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish ChouduryFebruary 26th, 2021
- A-DREAM/Alliance A032101 at ASCO 2026: ADT Interruption After Exceptional Response to ARPI in mHSPCMay 31st, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
